Education
About Us
Working with TipRanks
Follow Us
IDEAYA Biosciences (IDYA)
NASDAQ:IDYA
IDYA Analyst Ratings
Strong Buy
13 Buy
2 Hold
0 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
IDYA Stock 12 Month Forecast
Average Price Target
$49.08
▲(46.25% Upside)
| Highest Price Target$79.00 | Average Price Target$49.08 | Lowest Price Target$30.00 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
Citi
$64
Buy
90.70%
Upside
Initiated
12/12/25
We are initiating a 90-day upside Catalyst Watch on IDYA given what we believe is a favorable setup ahead of topline mPFS data from the Ph2/3 OptimUM-02 trial expected in 1Q26 for combo daro+criz in HLA*A2-negative metastatic uveal melanoma. Given positive Ph1/2 data from OptimUM-01, we expect mPFS in the Ph3 of ~7-8 months for the treatment group vs 2-3 months for control. Mgmt’s inclusion of 8 months in the expected PFS range (previously cited ~7 months) reflects the strength of Ph1/2 data, where 40% ECOG 1 still resulted in favorable PFS/OS (mOS ~21.1 months), thus potentially slightly lower ECOG 1 representation in Ph2/3 could be a tailwind on PFS. Regardless, 7 months is above the ~5.5 months needed for stat. sig.
Guggenheim
$50
Buy
48.99%
Upside
Reiterated
12/12/25
LifeSci Capital
$62
Buy
84.74%
Upside
Assigned
12/11/25
IDEAYA Biosciences: Promising Future with Innovative Dual KAT6/7 Inhibitor and Strong Financial Positions: IDYA this morning announced IND submission for IDE574, a differenated and potenal first-in-class dual KAT6/7 inhibitor, with plans to iniate monotherapy dose escalaon in 1Q 2026, share preclinical data at a 1H 2026 medical conference, and develop the asset primarily in HR+ breast and lung cancers. Recall that IDYA has previously & recently noted that the broader mechanism of dual KAT6/7 inhibion, relave to KAT6 alone (e.g., PFE, OLMA has a clinical-stage asset [LINK], PRLD has an IND-stage KAT6A degrader), should be able to enhance efficacy and possibly drive monotherapy acvity without combining with fulvestrant (parcularly as seen in preclinical data; see 10-Year R&D Day Slides 73-75).
Truist Financial
―
Buy
―
Reiterated
12/08/25
Mizuho Securities
$46
Buy
37.07%
Upside
Reiterated
12/08/25
RBC Capital
$41
Buy
22.17%
Upside
Reiterated
11/04/25
TD Cowen
―
Buy
―
Reiterated
11/04/25
Oppenheimer
$36
Buy
7.27%
Upside
Reiterated
11/04/25
BTIG
$62
Buy
84.74%
Upside
Reiterated
11/04/25
Barclays
$40
Buy
19.19%
Upside
Reiterated
11/04/25
UBS
$50
Buy
48.99%
Upside
Reiterated
10/24/25
J.P. Morgan
$74→$79
Buy
135.40%
Upside
Reiterated
10/23/25
Leerink Partners
$30→$33
Hold
-1.67%
Downside
Reiterated
10/21/25
Goldman Sachs
$27→$30
Hold
-10.61%
Downside
Reiterated
10/21/25
Citizens JMP
$45
Buy
34.09%
Upside
Reiterated
10/13/25
Analyst Type
Any
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
Citi
$64
Buy
90.70%
Upside
Initiated
12/12/25
We are initiating a 90-day upside Catalyst Watch on IDYA given what we believe is a favorable setup ahead of topline mPFS data from the Ph2/3 OptimUM-02 trial expected in 1Q26 for combo daro+criz in HLA*A2-negative metastatic uveal melanoma. Given positive Ph1/2 data from OptimUM-01, we expect mPFS in the Ph3 of ~7-8 months for the treatment group vs 2-3 months for control. Mgmt’s inclusion of 8 months in the expected PFS range (previously cited ~7 months) reflects the strength of Ph1/2 data, where 40% ECOG 1 still resulted in favorable PFS/OS (mOS ~21.1 months), thus potentially slightly lower ECOG 1 representation in Ph2/3 could be a tailwind on PFS. Regardless, 7 months is above the ~5.5 months needed for stat. sig.
Guggenheim
$50
Buy
48.99%
Upside
Reiterated
12/12/25
LifeSci Capital
$62
Buy
84.74%
Upside
Assigned
12/11/25
IDEAYA Biosciences: Promising Future with Innovative Dual KAT6/7 Inhibitor and Strong Financial Positions: IDYA this morning announced IND submission for IDE574, a differenated and potenal first-in-class dual KAT6/7 inhibitor, with plans to iniate monotherapy dose escalaon in 1Q 2026, share preclinical data at a 1H 2026 medical conference, and develop the asset primarily in HR+ breast and lung cancers. Recall that IDYA has previously & recently noted that the broader mechanism of dual KAT6/7 inhibion, relave to KAT6 alone (e.g., PFE, OLMA has a clinical-stage asset [LINK], PRLD has an IND-stage KAT6A degrader), should be able to enhance efficacy and possibly drive monotherapy acvity without combining with fulvestrant (parcularly as seen in preclinical data; see 10-Year R&D Day Slides 73-75).
Truist Financial
―
Buy
―
Reiterated
12/08/25
Mizuho Securities
$46
Buy
37.07%
Upside
Reiterated
12/08/25
RBC Capital
$41
Buy
22.17%
Upside
Reiterated
11/04/25
TD Cowen
―
Buy
―
Reiterated
11/04/25
Oppenheimer
$36
Buy
7.27%
Upside
Reiterated
11/04/25
BTIG
$62
Buy
84.74%
Upside
Reiterated
11/04/25
Barclays
$40
Buy
19.19%
Upside
Reiterated
11/04/25
UBS
$50
Buy
48.99%
Upside
Reiterated
10/24/25
J.P. Morgan
$74→$79
Buy
135.40%
Upside
Reiterated
10/23/25
Leerink Partners
$30→$33
Hold
-1.67%
Downside
Reiterated
10/21/25
Goldman Sachs
$27→$30
Hold
-10.61%
Downside
Reiterated
10/21/25
Citizens JMP
$45
Buy
34.09%
Upside
Reiterated
10/13/25
Best Analysts Covering IDEAYA Biosciences
1 Month
xxx
Success Rate
11/17 ratings generated profit
Average Return
+5.72%
reiterated a xxx
rating last month
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 64.71% of your transactions generating a profit, with an average return of +5.72% per trade.
3 Months
xxx
Success Rate
15/23 ratings generated profit
Average Return
+11.13%
assigned a xxx
rating 2 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 65.22% of your transactions generating a profit, with an average return of +11.13% per trade.
1 Year
Success Rate
18/23 ratings generated profit
Average Return
+47.06%
assigned a buy rating 2 days ago
Copying Charles Zhu's trades and holding each position for 1 Year would result in 78.26% of your transactions generating a profit, with an average return of +47.06% per trade.
2 Years
xxx
Success Rate
18/23 ratings generated profit
Average Return
+48.50%
assigned a xxx
rating 2 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 78.26% of your transactions generating a profit, with an average return of +48.50% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
IDYA Analyst Recommendation Trends
Rating
Aug 25
Sep 25
Oct 25
Nov 25
Dec 25
Strong Buy
6
25
33
33
16
Buy
4
8
10
13
12
Hold
8
13
11
12
7
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
18
46
54
58
35
Each month's total comprises the sum of three months' worth of ratings.
IDYA Financial Forecast
IDYA Stock Forecast FAQ
What is IDYA’s average 12-month price target, according to analysts?
Based on analyst ratings, IDEAYA Biosciences’s 12-month average price target is 49.08.
What is IDYA’s upside potential, based on the analysts’ average price target?
IDEAYA Biosciences has 46.25% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is IDYA a Buy, Sell or Hold?
IDEAYA Biosciences has a consensus rating of Strong Buy which is based on 13 buy ratings, 2 hold ratings and 0 sell ratings.
What is IDEAYA Biosciences’s price target?
The average price target for IDEAYA Biosciences is 49.08. This is based on 15 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $79.00 ,the lowest forecast is $30.00. The average price target represents 46.25% Increase from the current price of $33.56.
The highest analyst price target is $79.00 ,the lowest forecast is $30.00. The average price target represents 46.25% Increase from the current price of $33.56.
What do analysts say about IDEAYA Biosciences?
IDEAYA Biosciences’s analyst rating consensus is a Strong Buy. This is based on the ratings of 15 Wall Streets Analysts.
How can I buy shares of IDYA?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.